Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with (213)Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors

Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with

• Helisch, A.
• Kratochwil, C.
• Kleist, C.
• Krämer, S.
• Rosales Castillo, J. J.
• Dendl, K.
• Rathke, H.
• von Goetze, I.
• Schreckenberger, M.
• Jäger, D.
• Lindner, T.
• Mier, W.
• Giesel, F.
• Haberkorn, U.
• Röhrich, M.